“Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure”, J of Skin, vol. 8, no. 2, p. s379, Mar. 2024, doi: 10.25251/skin.8.supp.379.